XASEOGEN
Market cap4mUSD
Dec 24, Last price
0.38USD
1D
3.42%
1Q
-10.00%
Jan 2017
-99.88%
Name
Oragenics Inc
Chart & Performance
Profile
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 38 -71.37% | 132 51.20% | 87 | |||||||
Cost of revenue | 36,433 | 14,592 | 15,899 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (36,396) | (14,460) | (15,812) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (127) | 16 | ||||||||
Tax Rate | ||||||||||
NOPAT | (36,396) | (14,333) | (15,829) | |||||||
Net income | (20,656) 45.86% | (14,161) -9.96% | (15,728) -40.52% | |||||||
Dividends | (1,118) | |||||||||
Dividend yield | 2.22% | |||||||||
Proceeds from repurchase of equity | 850 | 69 | 23,665 | |||||||
BB yield | -6.71% | -0.55% | -46.99% | |||||||
Debt | ||||||||||
Debt current | 323 | 472 | 498 | |||||||
Long-term debt | 10 | 509 | 793 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (3,151) | (10,445) | (25,975) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (7,291) | (15,228) | (13,470) | |||||||
CAPEX | (128) | (44) | ||||||||
Cash from investing activities | (936) | (116) | (44) | |||||||
Cash from financing activities | 284 | (495) | 23,140 | |||||||
FCF | (34,198) | (16,017) | (15,654) | |||||||
Balance | ||||||||||
Cash | 3,484 | 11,427 | 27,266 | |||||||
Long term investments | ||||||||||
Excess cash | 3,482 | 11,420 | 27,261 | |||||||
Stockholders' equity | (204,622) | (183,968) | (168,501) | |||||||
Invested Capital | 208,113 | 197,602 | 195,784 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 2,250 | 2,009 | 1,882 | |||||||
Price | 5.63 -10.78% | 6.31 -76.43% | 26.76 -0.67% | |||||||
Market cap | 12,657 -0.10% | 12,670 -74.84% | 50,362 98.41% | |||||||
EV | 11,099 | 3,817 | 27,044 | |||||||
EBITDA | (36,368) | (14,416) | (15,771) | |||||||
EV/EBITDA | ||||||||||
Interest | 15 | 16 | ||||||||
Interest/NOPBT |